Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
42 Leser
Artikel bewerten:
(0)

New England Biolabs to Present Recent Advances in Enhancing Next Generation Sequencing Sample Preparation at AGBT 2014

IPSWICH, Mass., Feb. 11, 2014 /PRNewswire/ --New England Biolabs, Inc. (NEB®) will be presenting its recent innovations for next generation sequencing sample preparation at this year's Advances in Genome Biology and Technology (AGBT) conference from February 12th to 15th in Marco Island, Florida. These advances, which will include the ability to work with ever more complex and smaller sample inputs, as well as workflow enhancements, will be communicated via a mix of scientific posters, presentations and informal discussions. Scientists from its NEBNext® Applications and Product Development Division will be participating in the meeting and available to discuss these new tools and improvements in person.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

During the conference, NEB will be using Lanai Suite #185 at the Marco Island Marriott. The suite will be open from 9AM to 4PM on Feb 13th and 14th, and from 9AM to 12PM on Feb 15th. NEB will be hosting four informational and discussion sessions in the suite:

  • Overcoming challenges in total microbiome and organelle DNA sequencing (Feb 13th, 8-9AM EST)
  • Tools for improving RNA library preparation (Feb 13th, 5-6PM EST)
  • Improving library prep with FFPE DNA samples (Feb 14th, 8-9AM EST)
  • Low-input ChIP-Seq library prep (Feb 15th 8-9AM EST)

"NEB scientists have been participating in the AGBT conference since its first year," said Fiona Stewart, Product Marketing Manager, Next Generation Sequencing at NEB. "We are once again looking forward to being able to present our latest innovations and meeting with NGS scientists in the energetic and stimulating environment that AGBT provides."

NEB will also present six posters at the meeting. These will include data on a range of projects including the development of novel NEBNext® technologies to enable improved enrichment and library preparation of challenging samples, including microbiome and clinical FFPE RNA samples.

For more information on the AGBT conference, visit http://agbt.org
For more information on the NEBNext line of reagents for sample preparation, visit NEBNext.com.

About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, library preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com

NEW ENGLAND BIOLABS®, NEB® AND NEBNEXT® are registered trademarks of
New England Biolabs, Inc.

SOURCE New England Biolabs, Inc.

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.